StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report released on Thursday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on MRNS. JMP Securities dropped their price objective on shares of Marinus Pharmaceuticals from $19.00 to $18.00 and set a market outperform rating for the company in a report on Wednesday, March 8th. HC Wainwright reissued a buy rating and set a $27.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, March 8th. SVB Leerink lowered their price target on shares of Marinus Pharmaceuticals from $27.00 to $23.00 and set an outperform rating for the company in a report on Monday, January 23rd. Cantor Fitzgerald reaffirmed an overweight rating and issued a $28.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, March 8th. Finally, Royal Bank of Canada lowered their price target on shares of Marinus Pharmaceuticals from $23.00 to $22.00 and set an outperform rating for the company in a report on Wednesday, March 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of Moderate Buy and a consensus price target of $27.50.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $6.79 on Thursday. The firm has a 50-day simple moving average of $6.36 and a two-hundred day simple moving average of $5.68. Marinus Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $12.37. The company has a debt-to-equity ratio of 0.90, a current ratio of 10.09 and a quick ratio of 10.09.

Institutional Trading of Marinus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRNS. MetLife Investment Management LLC raised its position in Marinus Pharmaceuticals by 63.8% in the 1st quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company’s stock worth $190,000 after purchasing an additional 7,928 shares during the period. Charles Schwab Investment Management Inc. raised its position in Marinus Pharmaceuticals by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 2,281 shares during the period. Renaissance Technologies LLC purchased a new stake in Marinus Pharmaceuticals in the 1st quarter worth about $317,000. Goldman Sachs Group Inc. raised its position in Marinus Pharmaceuticals by 3.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 156,949 shares of the biopharmaceutical company’s stock worth $1,468,000 after purchasing an additional 5,380 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Marinus Pharmaceuticals in the 1st quarter worth about $40,000. 86.88% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

(Get Rating)

Marinus Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.